OY-TES-1在肝细胞癌中的表达及抗体血清学分析

AIM: To investigate OY-TES-1 expression and serum immunoreactivity in human hepatocellular carcinoma (HCC) and explore the possibility of using OY-TES-1 as a target for immunotherapy and auxiliary diagnosis of HCC. METHODS: The expression of OY-TES-1 mRNA and protein was detected by real-time PCR and immunohistochemistry, respectively. The presence of serum OY-TES-1 antibody in normal individuals and patients with HCC or hepatocirrhosis was determined by enzyme-linked immunosorbent assay (ELISA) using purified OYTES-1 as the antigen. The clinical significance of OY-TES-1 expression and serum immunoreactivity in HCC was then analyzed. RESULTS: The positive rates of OY-TES-1 mRNA expression in HCC and tumor-adjacent tissue were 73.21% (41/56) and 64.86% (24/37), respectively, showing no significant difference (P＞0.05). The expression level of OY-TES-1 mRNA in HCC tissue was significantly higher than that in tumor-adjacent tissue (P＜0.05). The expression level of OY-TES-1 mRNA was correlated with histological grade of HCC. The positive rate of OY-TES-1 protein expression in HCC tissue was 40% (4/10). The positive rate of serum OY-TES-1 antibody was 20% in HCC patients, while no serum reactivity to OY-TES-1 was detected in 76 normal individuals and 17 patients with hepatocirrhosis. No correlation was found between the presence of OY-TES-1 antibody and clinical and pathological parameters in HCC. CONCLUSION: OY-TES-1 shows high-level expression and high serum immunoreactivity in HCC and is therefore a potential target for antigen-specific immunotherapy and auxiliary diagnosis of HCC.